Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avigen, Inc.
AV513 reported to be safe, improves bleeding times in animal model of severe hemophilia A
June 23rd, 2006
Avigen, Inc., (AVGN) announced a presentation of data for its orally administered drug candidate, AV513, for the treatment of hemophilia and related bleeding disorders at the 2006 World Federation of Hemophilia Congress. The data presented show that AV513, a particular type of fucoidan, was safe and able to significantly improve the bleeding times in a well-studied naturally occurring animal model of severe hemophilia A. In humans, AV513 has the potential to improve hemophilia therapy by reducing the frequency of factor infusion, resulting in both decreased cost and improved quality of life for patients and caregivers. Hemophilia is an inherited...
Source: Biotech Law Weekly (2006-06-23)
|
